



Urogenital Neoplasms Pathology

Guest Editor:

Dr. Carlo Introini

Unit of Urology, Department of
Abdominal Surgery, Galliera
Hospital, 16128 Genoa, Italy

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Uro-oncological diseases affect a large population of middle and advanced age in both sexes. The anatomical extension of the urinary tract determines diagnostic difficulties that require ever more innovative technology. Small-caliber fiber-optic instruments and high-definition vision systems increase diagnostic accuracy. Equally, the histopathological, molecular and genetic methods of investigation allow the resolution of the differential diagnosis. The treatment of urological neoplasms relies on more comfortable techniques for the patient, such as laparoscopy and robotic surgery, which make it possible to obtain a high standard of care and functional preservation by reducing the hospitalization time. Robotic surgery, in particular, finds application in all intra-abdominal urological neoplasms, and for this reason it has expanded all over the world. Urologists who have extensive experience in these areas are invited to contribute their experiences, projects and achievements to this Special Issue.

Dr. Carlo Introini
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)